Trial Profile
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Mipetresgene autoleucel; NY ESO-1 loaded dendritic cell vaccine
- Indications Solid tumours
- Focus Adverse reactions
- 19 Apr 2023 Results(n=26 from studies NCT00910650, NCT02070406, NCT01697527, NCT03240861) assessing Patients baseline preinfusion serum cytokine levels via Luminex Immunoassay presented at the 114th Annual Meeting of the American Association for Cancer Research
- 26 Feb 2019 Status changed from recruiting to discontinued.
- 20 Dec 2018 Results safety, feasibility, and antitumor efficacy of transgenic ACT with DC vaccination, with and without CTLA-4 blockade with ipilimumab from NCT02070406 and NCT01697527, published in the Clinical Cancer Research.